VivoSeq
Nephrology

Stage 5 Chronic Kidney Disease

16

Pipeline Programs↗

0

Active Trials↗

13

Companies Involved↗

Stage 5 Chronic Kidney Disease is an emerging landscape with 16 programs across 13 companies. The most active players are AbbVie, AstraZeneca, Takeda. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

21/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3Takeda logo

Takeda

2 programs

ApprovedOtsuka logo

Otsuka

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

16 of 18 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody16%Protein / enzyme16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Terminated·AbbVie logoAbbVie·Phase 3·NCT04064827·2 enrolled
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
Completed·AbbVie logoAbbVie·Phase 3·NCT01382212·13 enrolled
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
Completed·OOPKO IP Holdings II, Inc.·Phase 2·NCT00742716·41 enrolled
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)
Completed·PPharmacosmos A/S·Phase 1·NCT01469078·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)